Clarity in cell line development

Accelerating the development of novel biological therapies

04/06/20 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)

In 2010, ten of the top ten drugs were small molecules and today, seven of the top ten drugs are recombinant proteins. This represents a multi-billion dollar sea change in the drug industry. As the portfolio of drug modalities shifts towards biopharma, cell line development laboratories are forced to keep pace with the increasing pressures to express a wider format of proteins in mammalian cell lines.

Join us for our X-Talks Webinar on 4th June to hear from Mark Stockdale and our partner, ATUM, as they discuss the importance of efficient cell line development in the development of novel biological therapies. Mark and Dr Oren Beske will share their insights on how to optimize the use of technology to accelerate workflows in CLD in order to generate high-quality cell lines.

From DNA to lead clone, there is a myriad of choices for cell line development in terms of biology, seamless technology and core instrumentation. To navigate these choices, this webinar will present the drivers needed to set up a new cell line development laboratory or scale-out production, as well as discuss viable present-day solutions.

Register for this free webinar to learn more about Solentim and ATUM’s technology and how to accelerate cell line development in order to generate high-quality master cell banks.

Meet the Amalgamators

Mark Stockdale, Amalgamator of Business and Biology, Solentim Ltd

Mark Stockdale is a keen technology pathfinder and works within Solentim to amalgamate the technical and business functions within the company. Prior to Solentim, he worked as a Group Leader at Horizon Discovery Ltd, a scientist within Lonza Biologics, Cyclacel Ltd and started his career at Pfizer. With over 15 years of professional experience in cell line development and drug discovery, his passion is to bring new technologies to bear on unmet needs and provides great insight into the future technology requirements in stable cell line development.

Oren Beske, Amalgamator of Business and Biology, ATUM

Dr Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start up antibody discovery platform company. Dr Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.

 

 

 

Register for the free webinar

Learn more about Solentim and ATUM’s technology and how to accelerate cell line development in order to generate high-quality master cell banks.

4th June 2020

11am EDT (NA) | 4pm BST (UK) | 5pm CEST (EU-Central)

Translate »